KH-3 (drug)

Last updated

KH-3 (drug)
KH-3 structure.png
Identifiers
  • (E)-3-[5-[(4-tert-butylphenyl)sulfonylamino]-1-benzothiophen-2-yl]-N-hydroxyprop-2-enamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C21H22N2O4S2
Molar mass 430.54 g·mol−1
3D model (JSmol)
  • CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(C=C2)SC(=C3)/C=C/C(=O)NO
  • InChI=1S/C21H22N2O4S2/c1-21(2,3)15-4-8-18(9-5-15)29(26,27)23-16-6-10-19-14(12-16)13-17(28-19)7-11-20(24)22-25/h4-13,23,25H,1-3H3,(H,22,24)/b11-7+
  • Key:RIYPLPNXICDUCS-YRNVUSSQSA-N

KH-3 is an experimental drug which acts as an inhibitor of the RNA-binding HuR protein. Elevated levels of HuR are found in many forms of cancer, and KH-3 is being researched for potential applications in cancer treatment. [1] [2] [3] [4] [5] [6] [7] [8]

See also

References

  1. ↑ Wu X, Gardashova G, Lan L, Han S, Zhong C, Marquez RT, et al. (April 2020). "Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis". Communications Biology. 3 (1): 193. doi:10.1038/s42003-020-0933-1. PMC   7181695 . PMID   32332873.
  2. ↑ Liu S, Huang Z, Tang A, Wu X, Aube J, Xu L, et al. (June 2020). "Inhibition of RNA-binding protein HuR reduces glomerulosclerosis in experimental nephritis". Clinical Science. 134 (12): 1433–1448. doi:10.1042/CS20200193. PMC   8086301 . PMID   32478392.
  3. ↑ Dong R, Chen P, Polireddy K, Wu X, Wang T, Ramesh R, et al. (November 2020). "An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells". Molecular Cancer Therapeutics. 19 (11): 2267–2277. doi:10.1158/1535-7163.MCT-19-0822. PMC   7921213 . PMID   32879054.
  4. ↑ Wei L, Zhang Q, Zhong C, He L, Zhang Y, Armaly AM, et al. (October 2023). "Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy". Molecular Oncology. 17 (10): 1962–1980. doi:10.1002/1878-0261.13478. PMC   10552894 . PMID   37357618.
  5. ↑ You H, Song G, Xu Z, Chen S, Shen W, Liu H, et al. (February 2024). "HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1". Journal of Translational Medicine. 22 (1): 178. doi: 10.1186/s12967-024-04970-w . PMC   10874581 . PMID   38369471.
  6. ↑ Wei L, Kim SH, Armaly AM, Aubé J, Xu L, Wu X (December 2024). "RNA-binding protein HuR inhibition induces multiple programmed cell death in breast and prostate cancer". Cell Communication and Signaling. 22 (1): 580. doi: 10.1186/s12964-024-01916-z . PMC   11613925 . PMID   39627778.
  7. ↑ Wei L, Kim SH, Armaly AM, Aubé J, Xu L, Wu X (December 2024). "HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer". npj Precision Oncology. 8 (1): 286. doi:10.1038/s41698-024-00780-x. PMC   11661992 . PMID   39706893.
  8. ↑ Arneson-Wissink PC, Pelz K, Worley B, Mendez H, Pham P, McCarthy G, et al. (December 2024). "The RNA-binding protein HuR impairs adipose tissue anabolism in pancreatic cancer cachexia". bioRxiv. doi:10.1101/2024.12.27.630549. PMC   11703191 . PMID   39763867.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.